Department of Pharmacology, All India Institute of Medical Sciences, New Delhi 110029, India.
Curr Pharm Biotechnol. 2010 Dec;11(8):855-60. doi: 10.2174/138920110793262051.
The stem bark of Terminalia arjuna (Roxb.) is used by the Ayurvedic physicians in India for the treatment of various cardiovascular diseases, collectively referred to as hritroga. It has been extensively studied in animal models to demonstrate cardioprotective properties, ranging from positive inotropic- , hypolipdemic-, coronary vasodilatory- and antioxidant effects to induction of stress protein in heart. Various bioactive compounds, like triterpinoids, tannins, flavonoids and minerals have been isolated from the stem bark. A number of clinical studies have also reported its beneficial effects in patients of chronic stable angina, endothelial dysfunction, heart failure and even ischemic mitral regurgitation. However, there are some identified lacunae, like standardisation of the 'drug', toxicity studies along with pharmacological interactions with other drugs and large multicentre randomized clinical trials, before its use by modern medicine is acceptable.
诃子的茎皮在印度被阿育吠陀医师用于治疗各种心血管疾病，统称为 hritroga。它在动物模型中得到了广泛研究，以证明其具有心脏保护特性，包括正性变力作用、降血脂作用、冠状血管舒张作用和抗氧化作用，以及诱导心脏应激蛋白。已经从茎皮中分离出各种生物活性化合物，如三萜类、单宁、类黄酮和矿物质。一些临床研究还报告了它在慢性稳定型心绞痛、内皮功能障碍、心力衰竭甚至缺血性二尖瓣反流患者中的有益作用。然而，在现代医学可以接受使用诃子之前，还存在一些确定的空白，如“药物”的标准化、毒性研究以及与其他药物的药理学相互作用，以及大型多中心随机临床试验。
